I think that stigma creates problems, for both patients and clinicians.
Research Applications of Semaglutide GLP-1 receptor pharmacology in pancreatic beta-cell models and HEK293 cells expressing the human GLP-1R, where semaglutide is the standard long-acting agonist used to characterize receptor binding affinity, EC values, and downstream cAMP signalling
May your B12 levels stay robust, your GLP-1 therapy stay effective, and your protocols stay evidence-based.
Slowing the dose escalation schedule, temporarily returning to a lower dose, or holding at the current dose longer than recommended are options that can improve tolerability while still achieving therapeutic benefits
Some people experience a physical reaction called vasomotor rhinitis shortly after their dose as the body reacts to the increase in GLP-1 levels
Semaglutide is often a long-term therapy